Cisplatin and ototoxicity in childhood: the perspective of supporting otoprotective agentes.

Braz J Biol

Universidade Estadual de Ciências da Saúde de Alagoas - UNCISAL, Maceió, AL, Brasil.

Published: August 2024

Cisplatin is an antineoplastic medicine used in the treatment for various types of cancer. Among its side effects is ototoxicity, which may result in a bilateral and irreversible hearing loss. The ototoxic effect in the pediatric population has a bigger impact as it compromises language acquisition. The discovery of drugs with otoprotective effects and the optimal way to administer them have become significant challenges in minimizing the impact of cisplatin regarding auditory function. The objective was to understand otoprotective drugs and their relevance in the preventive treatment to cisplatin-induced ototoxicity in childhood. An integrative review was conducted by consulting databases including PubMed, Bireme, MedLine, LILACS, SciELO, and ClinicalTrials.gov. The search strategy was performed by crossing descriptors (DeCS and MeSH) and free terms. Studies published in English, Spanish, and Portuguese were selected, with no publication year restrictions. Subsequently, articles were selected according to inclusion and exclusion criteria. A total of 736 articles were found in PubMed, 431 in Bireme, 425 in MedLine, 6 in LILACS, 0 in SciELO, and 4 in ClinicalTrials.gov. After document analysis, 12 articles were selected for full analysis. Evidence was found for 8 substances with potential otoprotective effects when used with cisplatin, which tend to minimize the impact of cisplatin regarding auditory function. The substances found were: Amifostine, Dexamethasone, Genistein, Ginkgo Biloba, Lycopene, N-acetylcysteine, Polydatin also Sodium Thiosulfate. In general, these drugs are applied before, during, or after cisplatin infusion, depending on the chosen drug, via intravenous, oral, or transtympanic injections, acting as antioxidant therapy. The biochemical effects of these substances are relevant to their potential otoprotective properties, including the inactivation of oxygen free radicals and electrophilic platinum species. The use of these substances can reduce ototoxicity, decreasing cisplatin-induced hearing loss and improving the confort of life, especially for children.

Download full-text PDF

Source
http://dx.doi.org/10.1590/1519-6984.279117DOI Listing

Publication Analysis

Top Keywords

ototoxicity childhood
8
hearing loss
8
otoprotective effects
8
impact cisplatin
8
cisplatin auditory
8
auditory function
8
medline lilacs
8
lilacs scielo
8
scielo clinicaltrialsgov
8
articles selected
8

Similar Publications

Background: The incorporation of anti-GD2 antibodies such as ch14.18/SP2/0 into the multimodal treatment of high-risk neuroblastoma (HR-NB) patients has improved their outcomes. As studies assessing the long-term outcomes, long-term sequelae, and health-related quality of life (HRQoL) of this treatment are limited, this retrospective analysis aimed to explore these.

View Article and Find Full Text PDF

Bedřich Smetana's illness associated with complete hearing loss has been linked to various diseases in a long-running discussion. Senile dementia, atherosclerosis, progressive paralysis in lues are mentioned, while the ototoxicity of mercury is neglected. Its high concentration in the composer's skeletal remains was demonstrated by the authors of this article immunohistochemically and especially by the neutron activation analysis (NAA) method 23 years ago.

View Article and Find Full Text PDF
Article Synopsis
  • The ACCL0431 trial showed that sodium thiosulfate (STS) effectively reduces cisplatin-induced hearing loss in young patients aged 1-18.
  • A secondary analysis revealed that the incidence of hearing loss was significantly lower in those receiving STS (22.4%) compared to those who were only observed (54.0%).
  • The best protective effects of STS were seen in younger children (under 5 years) and those with specific cancers like neuroblastoma, indicating the need for tailored treatment strategies based on patient characteristics.
View Article and Find Full Text PDF

Healthcare professionals' knowledge and practices in managing ototoxicity in children with cancer.

S Afr J Commun Disord

November 2024

Department of Audiology, Faculty of Health Sciences, University of KwaZulu-Natal, Durban.

Background:  Platinum-based chemotherapy poses a risk of ototoxic hearing loss, the effects of which can be devastating in paediatrics with cancer. Childhood hearing loss significantly impacts speech and language acquisition, and educational, psychosocial and emotional development, consequently negatively impacting quality of life. Adequate knowledge and effective management by healthcare professionals in the team managing paediatrics with cancer are, therefore, pivotal to mitigating the severity and impact on quality of life.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!